This report by Wioletta M. Zelek stems from the U.K.
"And LERONLIMAB for inflammation triggered by acute SAR-CoV-2 infection.."

Long-Covid is a very different disease...manifesting with low-grade inflammation as opposed to the acute Hyper-Inflammation state typifying some cases of acute COVID-19.

Here's the best part..."A proof-of-concept study or Clinical Trial using complement inhibitors is needed to Validate this Hypothesis...WOW...what a concept...All from 5000 miles away...to our too sunny shores.